EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Reduced Levels of miR-145-3p Drive Cell Cycle Progression in Advanced High-Grade Serous Ovarian Cancer

Eva González-Cantó, Mariana Monteiro, Cristina Aghababyan iD, Ana Ferrero-Micó, Sergio Navarro-Serna iD, Maravillas Mellado-López iD, Sarai Tomás-Pérez, Juan Sandoval, Antoni Llueca iD, Alejandro Herreros-Pomares, Juan Gilabert-Estellés, Vicente Pérez-García iD und 1 weitere

Cells · 2024

DOI: 10.3390/cells13221904 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Eva González-Cantó und 12 weiteren Autor:innen. Beteiligte Einrichtung: Research Laboratory in Biomarkers in Reproduction, Obstetrics and Gynecology, Research Foundation of the General University Hospital of Valencia, 460…. Hauptthemen laut MEDLINE: MicroRNAs, Ovarian Neoplasms, Gene Expression Regulation, Neoplastic, Cell Movement. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Instituto de Salud Carlos III, Generalitat Valenciana, "Sociedad de Obstetricia y Ginecología de la Comunidad Valenciana" (SOGCV).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

High-grade serous ovarian cancer (HGSOC) is the most lethal form of gynecologic cancer, with limited treatment options and a poor prognosis. Epigenetic factors, such as microRNAs (miRNAs) and DNA methylation, play pivotal roles in cancer progression, yet their specific contributions to HGSOC remain insufficiently understood. In this study, we performed comprehensive high-throughput analyses to identify dysregulated miRNAs in HGSOC and investigate their epigenetic regulation. Analysis of tissue samples from advanced-stage HGSOC patients revealed 20 differentially expressed miRNAs, 11 of which were corroborated via RT-qPCR in patient samples and cancer cell lines. Among these, miR-145-3p was consistently downregulated post-neoadjuvant therapy and was able to distinguish tumoural from control tissues. Further investigation confirmed that DNA methylation controls MIR145 expression. Functional assays showed that overexpression of miR-145-3p significantly reduced cell migration and induced G0/G1 cell cycle arrest by modulating the cyclin D1-CDK4/6 pathway. These findings suggest that miR-145-3p downregulation enhances cell proliferation and motility in HGSOC, implicating its restoration as a potential therapeutic target focused on G1/S phase regulation in the treatment of HGSOC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicroRNAsOvarian NeoplasmsGene Expression Regulation, NeoplasticCell MovementCell CycleCell ProliferationHumansFemaleCell Line, TumorDNA MethylationDown-RegulationNeoplasm GradingCystadenocarcinoma, SerousCyclin-Dependent Kinase 6

Stichwörter der Autor:innen

DNA methylationcell cycle proliferationcyclin D1-CDK4/6 pathwayhigh-grade serous ovarian cancermiR-145-3pmiRNAs

Substanzen

MicroRNAsMIRN145 microRNA, humanCyclin-Dependent Kinase 6

Autor:innen und Institutionen

  • Research Laboratory in Biomarkers in Reproduction, Obstetrics and Gynecology, Research Foundation of the General University Hospital of Valencia, 46014 Valencia, Spain.
  • Bioinformatics and Genomics Department, Saphetor SA, 1015 Lausanne, Switzerland.
  • Department of Obstetrics and Gynecology, General University Hospital of Valencia Consortium, 46014 Valencia, Spain.
  • Research Laboratory of Molecular Mechanisms of Placental Invasion, Centro de Investigación Príncipe Felipe, 46012 Valencia, Spain.
  • Epigenomics Unit, La Fe Health Research Institute, 46026 Valencia, Spain.
  • Biomarkers and Precision Medicine Unit (UByMP), La Fe Health Research Institute, 46026 Valencia, Spain.

ORCID-Profile: Cristina Aghababyan, Sergio Navarro-Serna, Maravillas Mellado-López, Antoni Llueca, Vicente Pérez-García, Josep Marí-Alexandre

Förderung

  • Instituto de Salud Carlos III
  • Generalitat Valenciana
  • "Sociedad de Obstetricia y Ginecología de la Comunidad Valenciana" (SOGCV)
  • Fundacio Investigacio Hospital General Universitari De Valencia
  • Asociación Española Contra el Cáncer
  • Ministerio de Ciencia, Innovación y Universidades
  • Fundación Ramón Areces
  • Amunt Contra el Càncer

Zitieren

APA

González-Cantó, E., Monteiro, M., Aghababyan, C., Ferrero-Micó, A., Navarro-Serna, S., Mellado-López, M., Tomás-Pérez, S., Sandoval, J., Llueca, A., Herreros-Pomares, A., Gilabert-Estellés, J., Pérez-García, V., & Marí-Alexandre, J. (2024). Reduced Levels of miR-145-3p Drive Cell Cycle Progression in Advanced High-Grade Serous Ovarian Cancer. Cells. https://doi.org/10.3390/cells13221904

Vancouver

González-Cantó E, Monteiro M, Aghababyan C, Ferrero-Micó A, Navarro-Serna S, Mellado-López M, et al. Reduced Levels of miR-145-3p Drive Cell Cycle Progression in Advanced High-Grade Serous Ovarian Cancer. Cells. 2024. doi:10.3390/cells13221904

BibTeX
@article{GonzlezCant2024,
  author = {González-Cantó, Eva and Monteiro, Mariana and Aghababyan, Cristina and Ferrero-Micó, Ana and Navarro-Serna, Sergio and Mellado-López, Maravillas and Tomás-Pérez, Sarai and Sandoval, Juan and Llueca, Antoni and Herreros-Pomares, Alejandro and Gilabert-Estellés, Juan and Pérez-García, Vicente and Marí-Alexandre, Josep},
  title = {Reduced Levels of miR-145-3p Drive Cell Cycle Progression in Advanced High-Grade Serous Ovarian Cancer},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13221904}
}
Kostenlos starten →